Clinical Biomarker Data for Anifrolumab Response in Systemic Lupus Erythematosus

A 2026 study by Koichi Kimura prospectively enrolled 31 patients with systemic lupus erythematosus (SLE) initiating anifrolumab treatment. It analyzes immune cell subsets and type I interferon-associated markers via flow cytometry to identify biomarkers predicting 6-month clinical response.

Use Cases

• Predict 6-month BICLA response and glucocorticoid tapering success using baseline CD317 expression levels on T cells.
• Compare the discriminative power of flow cytometry biomarkers like CD317 on T cells, CD317 on B cells, and CD169 on monocytes against the four-gene IFN gene signature measured by qPCR.
• Analyze baseline T-peripheral-helper–cell frequency with respect to patient classification as responders or non-responders.

Strengths

• Data from a prospective clinical study of 31 SLE patients provides a focused cohort for biomarker analysis.
• Identifies CD317 expression on T cells as a predictive biomarker with an AUC of 0.89 for separating responders from non-responders.
• Includes clinical response assessment based on two criteria: BICLA response and successful glucocorticoid tapering.

Limitations

• Small sample size of 31 patients limits statistical power and generalizability of findings.
• Biomarker findings are contingent upon further validation in larger, independent cohorts.
• Data is presented in a PDF report; underlying tabular data for individual patient measurements is not directly accessible.

Provenance

Source

Koichi Kimura via figshare.

Collection Method

Prospective clinical study evaluating immune cell subsets and type I IFN-associated markers by flow cytometry.

Time Range

Study period not specified; results published in 2026.

Freshness

Last updated March 2026.

Geography

null